H pylori drug regimen
Reading File
Finding Sources
Searching PubMed
"Helicobacter pylori" AND eradication AND treatment
Reading File
Finding Sources
Reading File
Reading File
Reading File
Excellent - I have comprehensive data from Harrison's 22E (2025), Katzung, and Rosen's. Here is the full answer:
H. pylori Eradication Regimens
No single drug eradicates H. pylori. All effective regimens combine a PPI + 2-3 antibiotics, always given for 10-14 days (14 days is superior to 7-10 days). The target eradication rate is 85-90%.
First-Line Regimens
1. Clarithromycin Triple Therapy
Use only if: no prior macrolide exposure AND local clarithromycin resistance <15%
| Drug | Dose | Frequency |
|---|---|---|
| PPI (standard or double dose) | e.g. omeprazole 20-40 mg | BID |
| Clarithromycin | 500 mg | BID |
| Amoxicillin | 1 g | BID |
| or Metronidazole (if penicillin-allergic) | 500 mg | BID |
Duration: 14 days
- Prevpac is a prepackaged formulation of lansoprazole + clarithromycin + amoxicillin taken BID x 14 days.
2. Bismuth Quadruple Therapy (BQT)
Now often recommended as first-line due to rising clarithromycin resistance.
| Drug | Dose | Frequency |
|---|---|---|
| PPI (standard dose) | e.g. omeprazole 20 mg | BID |
| Bismuth subcitrate 120-300 mg or subsalicylate 300-525 mg | QID | |
| Tetracycline | 500 mg | QID |
| Metronidazole | 250-500 mg | QID (or TID-QID for 500 mg) |
Duration: 10-14 days
- A combination capsule (Pylera: bismuth subcitrate + metronidazole + tetracycline) is commercially available - take 3 capsules QID + PPI BID.
3. Concomitant Therapy (Non-bismuth Quadruple)
| Drug | Dose | Frequency |
|---|---|---|
| PPI | standard dose | BID |
| Clarithromycin | 500 mg | BID |
| Amoxicillin | 1 g | BID |
| Nitroimidazole (metronidazole/tinidazole) | 500 mg | BID |
Duration: 10-14 days
- Eradication rates of 81-96% reported. Useful where both clarithromycin and metronidazole resistance is moderate.
4. Sequential Therapy
| Phase | Drugs | Duration |
|---|---|---|
| Phase 1 | PPI (BID) + Amoxicillin 1 g (BID) | 5-7 days |
| Phase 2 | PPI (BID) + Clarithromycin 500 mg (BID) + Nitroimidazole 500 mg (BID) | 5-7 days |
Total duration: 10-14 days
5. Hybrid Therapy
| Phase | Drugs | Duration |
|---|---|---|
| Phase 1 | PPI (BID) + Amoxicillin 1 g (BID) | 7 days |
| Phase 2 | PPI + Amoxicillin + Clarithromycin 500 mg + Nitroimidazole 500 mg (all BID) | 7 days |
Total duration: 14 days
Fluoroquinolone-Based Regimens (Rescue/Second-Line)
Used when first-line fails, particularly if bismuth-based therapy was not used initially.
Levofloxacin Triple
| Drug | Dose | Frequency |
|---|---|---|
| PPI (standard or double dose) | BID | |
| Levofloxacin | 500 mg | QD |
| Amoxicillin | 1 g | BID |
Duration: 5-7 days (some guidelines recommend 14 days)
Levofloxacin Sequential
- Phase 1: PPI + Amoxicillin x 5-7 days
- Phase 2: PPI + Levofloxacin + Nitroimidazole x 5-7 days
After Antibiotic Therapy
- Continue PPI once daily for a total of 4-6 weeks after completing antibiotics to ensure complete ulcer healing.
- Confirm eradication with urea breath test (UBT) or fecal antigen test (FAT) at least 4 weeks after finishing antibiotics.
- Stop PPIs 2 weeks before testing to avoid false-negative results.
Key Points on Resistance
- Rising clarithromycin resistance is the main reason triple therapy is failing globally - BQT or concomitant therapy is increasingly preferred as first-line.
- If first-line regimen fails, avoid re-using clarithromycin or metronidazole if those were already used. Switch drug class (e.g., use levofloxacin or bismuth-based rescue).
- Antibiotic susceptibility testing (culture or PCR-based) is ideal before second-line treatment.
Indications for Treatment
- Peptic ulcer disease (gastric or duodenal) - regardless of whether active or in remission
- Gastric MALT lymphoma (60-90% achieve complete remission with eradication alone)
- Uninvestigated dyspepsia in patients <60 years
- Before long-term NSAID use (especially with prior PUD history)
- Unexplained iron-deficiency anemia or idiopathic thrombocytopenic purpura
- First-degree relatives of gastric cancer patients
- Post-resection of early gastric cancer
Sources: Harrison's Principles of Internal Medicine 22E (2025), Table 335-4; Katzung's Basic and Clinical Pharmacology 16th Ed.; Rosen's Emergency Medicine Box 75.5. Recent meta-analysis (PMID 39824392) confirms eradication therapy reduces gastric cancer risk.
This is a shared conversation. Sign in to Orris to start your own chat.